Here’s what’s in store for you in today’s issue:

🍄 First psychedelic studies program in Canada

🍄 How to cure depression in two hours 🤯

🍄 Psilocybin works twice as well as nicotine patches!

🍄 Two stock that could quadruple in price 📈

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Can DMT really help cure addiction?

In this episode of the Daily Mushroom Podcast, we have David Mayoh, communication manager for Entheon Biomedical. David talks about how psychedelic therapy changed his life and how DMT can help those who are suffering from addiction.

How to cure depression in two hours

GH Research (GHRS) discovered that the most powerful psychedelic, 5-MeO-DMT (aka toad venom), is highly effective at curing treatment-resistant depression.

Out of eight patients, seven were in remission from depression just one day after receiving the company’s proprietary formulation, and five of those were in remission in as little as two hours. 

All eight patients showed improved depression scores, with an average reduction of 76%. 

Psilocybin works twice as well as nicotine patches!

Dr. Matthew Johnson’s research found that 59% of nicotine-addicted patients remained abstinent from smoking for 12 months after receiving a single macrodose of psilocybin. Only 28% of patients on a nicotine patch remained abstinent for the same time period.

His other research shows that multiple psilocybin doses can have an 80% success rate!

Psychedelics → spirituality → emotional regulation → happiness

A recent survey shows that spirituality increases with psychedelic use, and that increased spirituality is linked to improved emotional regulation. The findings suggest that better emotional regulation is associated with decreased scores for depression, anxiety, and disordered eating.

Reboot your brain 

Marcus Capone, a former Navy SEAL who was battling PTSD, finally got his life back after travelling to Mexico for an ibogaine treatment. 

He instantly felt like a huge weight had been lifted, as if his brain “was rebooted like a new operating system.”

“You can’t hide from the medicine. It’s going to reach down and it’s going to pull out everything that is affecting you,” he explains.

Ibogaine is a psychedelic substance found in the root  bark of the iboga tree! Learn more here.

The first psychedelic studies program in Canada

This semester, the University of Ottawa launched a three-course “microprogram” on Psychedelics and Spirituality. The school will offer a master’s program in psychedelics in the fall of 2022 and aims to develop a Ph.D. program after that!


“I was getting emails almost on a daily basis from people who wanted to know how they could become psychedelic therapists,” said Dr. Monica Williams, who created the program.

US government studies ibogaine

Delix Therapeutics, a private Boston-based company, is partnering with The National Institute on Drug Abuse (NIDA) to develop a treatment for substance abuse. The partnership will evaluate Delix’s non-hallucinogenic formulation of ibogaine, which has already shown promise of reducing alcohol- and heroin-seeking behavior.

BetterLife Pharma (BETR) found that its LSD formulation successfully increased exploratory and grooming behaviours in rats, two indicators of an antidepressant effect.

atai Life Sciences (ATAI) launched TryptageniX, a majority-owned joint venture with CB Therapeutics that will focus on discovering new compounds, both psychedelic and non-psychedelic.

Mycotopia Therapies (TPIA) is planning a $360M merger with Ei.Ventures to form PSLY.COM and intends to list on the NASDAQ. The new company would focus on Ei.Ventures’ flagship product Psilly, which combines psilocybin with other plant and fungi extracts for a synergistic effect.

Vine Ventures and MAPS formed a $70M special purpose vehicle called the Regenerative Financing Vine to fund MDMA research for PTSD and promote patient access.

An analyst at H.C. Wainwright predicted that Field Trip Health’s (FTRP) and COMPASS Pathways’ (CMPS) stocks could quadruple in value in the next 12 months! 🤑

GH Research (GHRS) and Numinus Wellness (NUMI) announced their financial highlights.

legal banner

Here’s what you missed in the legal world:

The Drug Enforcement Administration (DEA) and National Institute On Drug Abuse (NIDA) showed support for Biden’s plan to accelerate research on cannabis and certain psychedelics. The plan would reduce the requirements to research Schedule I substances, making them more similar to the Schedule II requirements. Read more…


4,000% of your daily vitamin D

The majority of people are deficient in vitamin D. Mushrooms could provide a solution!

Wild mushrooms are rich in the vitamin, but commercial production (which is often done in the dark) reduces concentration levels.

Scientists discovered that exposing mushrooms to UV radiation can increase vitamin D levels to over 4,000% of your daily value per serving! The exposure also causes mushrooms to produce more antioxidants and anti-inflammatory molecules.

Industry Quick Hits

Dec 6 – Novamind (NM) Opens New Salt Lake City Clinic with Specialized Focus on Substance Use Disorders Read more…

Dec 6 – Mydecine (MYCO) Files Full Patent Application Covering Multiple Families of Psilocin Analogs Read more…

Dec 8 – Ketamine One (MEDI) Adds Seattle Location To US Clinical Network Read more…

Dec 8 – Silo Wellness (SILO) Announces U.S. DTC Eligibility Read more…

Dec 8 – Nue Life announces donations to MAPS and Ketamine Research Foundation  Read more…

Dec 9 – Cannabis company Nextleaf Solutions (OILFF) Receives a Controlled Substance Dealers License Read more…

Video of the Week

Playlist of the Week